Literature DB >> 22133906

Symptom severity and attitudes toward medication: impacts on adherence in outpatients with schizophrenia.

Jaewon Yang1, Young-Hoon Ko, Jong-Woo Paik, Moon-Soo Lee, Changsu Han, Sook-Haeng Joe, In-Kwa Jung, Hyun-Gang Jung, Seung-Hyun Kim.   

Abstract

OBJECTIVE: The primary aim of this study was to compare electronic monitoring with other measures of adherence to antipsychotic medication in outpatients with schizophrenia. The secondary aim of the study was to analyze the relationships between adherence and other clinical parameters.
METHOD: Fifty-one patients diagnosed with schizophrenia were monitored over an eight-week period. Medication adherence was assessed using the Medication Event Monitoring System (MEMS), which is a bottle cap with a microprocessor that records the occurrence and times of bottle opening, patient self-reports, a clinician rating scale, and pill counts. Agreements among adherence measures and the relationships between adherence and other clinical factors were assessed.
RESULTS: The rate of non-adherence according to the MEMS was 41.2%, considerably higher than those of pill counting (7.8%), clinician rating scale (7.8%), or self-reporting (25.5%). Excitement, impulse control, and preoccupation symptoms on the Positive and Negative Syndrome Scale (PANSS) were higher in the non-adherent patients than in the adherent patients. The full Drug Attitude Inventory (DAI) score was higher in adherent versus non-adherent patients and the significant other subscale of the Multidimensional Scale of Perceived Social Support score was lower in the adherent patients. The Clinical Global Impression-Severity score was negatively correlated with adherence as measured by the MEMS (r=-0.426, p<0.05) and DAI scores were positively correlated with adherence according to the MEMS and the clinician rating scale (r=0.498, p<0.01 and r=0.387, p<0.05). Multivariate analysis showed that PANSS and DAI scores significantly contributed to MEMS adherence.
CONCLUSION: Adherence as measured by the MEMS showed a discrepancy with other measures of adherence in patients with schizophrenia. The severity of disease and attitudes toward medication were related to adherence. Further studies are needed to evaluate the impacts of medication adherence in schizophrenia.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22133906     DOI: 10.1016/j.schres.2011.11.008

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  29 in total

Review 1.  A scoping review of studies comparing the medication event monitoring system (MEMS) with alternative methods for measuring medication adherence.

Authors:  Mohamed El Alili; Bernard Vrijens; Jenny Demonceau; Silvia M Evers; Mickael Hiligsmann
Journal:  Br J Clin Pharmacol       Date:  2016-05-02       Impact factor: 4.335

Review 2.  Concordance of Adherence Measurement Using Self-Reported Adherence Questionnaires and Medication Monitoring Devices: An Updated Review.

Authors:  Alisha Monnette; Yichen Zhang; Hui Shao; Lizheng Shi
Journal:  Pharmacoeconomics       Date:  2018-01       Impact factor: 4.981

3.  Measuring adherence to antipsychotic medications for schizophrenia: Concordance and validity among a community sample in rural China.

Authors:  Dong Roman Xu; Wenjie Gong; Steve Gloyd; Eric D Caine; Jane Simoni; James P Hughes; Shuiyuan Xiao; Wenjun He; Bofeng Dai; Meijuan Lin; Juan Nie; Hua He
Journal:  Schizophr Res       Date:  2018-05-26       Impact factor: 4.939

4.  Correlates of Negative Attitudes towards Medication in People with Schizophrenia.

Authors:  Lucie Kondrátová; Daniel König; Karolína Mladá; Petr Winkler
Journal:  Psychiatr Q       Date:  2019-03

5.  Families and medication use and adherence among Latinos with schizophrenia.

Authors:  Mercedes Hernandez; Concepción Barrio
Journal:  J Ment Health       Date:  2016-10-01

6.  The effect of providing patient-specific electronically monitored antipsychotic medication adherence results on the treatment planning of prescribers of outpatients with schizophrenia.

Authors:  Paul A Nakonezny; Matthew J Byerly; Amit Pradhan
Journal:  Psychiatry Res       Date:  2013-03-06       Impact factor: 3.222

7.  Enhancing adherence, subjective well-being and quality of life in patients with schizophrenia: which role for long-acting risperidone?

Authors:  Cinzia Niolu; Emanuela Bianciardi; Giorgio Di Lorenzo; Claudia Marchetta; Ylenia Barone; Nicoletta Sterbini; Michele Ribolsi; Giorgio Reggiardo; Alberto Siracusano
Journal:  Ther Adv Psychopharmacol       Date:  2015-10

8.  Analysis of Medication Adherence and Its Influencing Factors in Patients with Schizophrenia in the Chinese Institutional Environment.

Authors:  Wei Yu; Jie Tong; Xirong Sun; Fazhan Chen; Jie Zhang; Yu Pei; Tingting Zhang; Jiechun Zhang; Binggen Zhu
Journal:  Int J Environ Res Public Health       Date:  2021-04-29       Impact factor: 3.390

9.  Short-term clinical stability and lack of insight are associated with a negative attitude towards antipsychotic treatment at discharge in patients with schizophrenia and bipolar disorder.

Authors:  Esteban Medina; Joan Salvà; Rubén Ampudia; Jorge Maurino; Juan Larumbe
Journal:  Patient Prefer Adherence       Date:  2012-08-29       Impact factor: 2.711

10.  Long-acting Injectable Antipsychotics in First-episode Schizophrenia.

Authors:  Hyun-Ghang Jeong; Moon-Soo Lee
Journal:  Clin Psychopharmacol Neurosci       Date:  2013-04-24       Impact factor: 2.582

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.